Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-cancer DC Cell Vaccination in Advanced Solid Tumors
NCT06477614Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2024
- Primary completion
- Dec 2030
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of gp96 antigen peptide complex sensitized dendritic cells in solid tumor (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Number of Patients with Dose Limiting Toxicity at 6 months. Started Jun 2024; status: recruiting.
02
Drugs
gp96 antigen peptide complex sensitized dendritic cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06477614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477614.